ZELIRA THERAPEUTICS LIMITED

ITURA

Topical preparations; Topical preparations that target symptoms associated with Peripheral Artery Disease (PAD) and Diabetic Neuropathies containing cannabinoids solely derived from hemp with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis; Topical preparations for treatment of pain associated with Peripheral Artery Disease (PAD) and Diabetic Neuropathies containing cannabinoids solely derived from hemp with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis;

Z

The mark consists of a stylized letter Z.;Preparations for medical purposes derived from cannabis for the prevention, management and treatment of opioid addiction, cancer including breast cancer, brain cancer and pancreatic cancer, pain, chronic pain, terminal illnesses, epilepsy, arthritis, crohn's disease, insomnia, diabetes, eczema, psychiatric diseases and disorders including mood disorders, anxiety disorders, sleep disorders, cognitive disorders, Alzheimer's, depression, autism and post-traumatic stress disorder; all of the foregoing containing or solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD;Color is not claimed as a feature of the mark.;Conducting clinical trials for others; research relating to science; provision of pharmaceutical research services; project management and planning of clinical trials, namely, consulting services for others in the field of design, planning, and implementation project management of clinical trials; research relating to pharmaceuticals; research relating to medicinal use of marijuana and cannabis; scientific research relating to medicinal use of cannabis; scientific research and development of medicinal cannabis products; medical research; scientific research for medical purposes; scientific research; all of the foregoing featuring only hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis;